[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579246":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":60,"collaborators":25,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":25,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University Hospital, Basel, Switzerland","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Protein Supplementation","EXPERIMENTAL","80 g protein supplementation per day (two bottles, each containing 40 g protein)",[13],"Dietary Supplement: Moltein PURE Protein Powder",{"label":15,"type":16,"description":17,"interventionNames":18},"Fluid restriction","ACTIVE_COMPARATOR","total daily fluid intake to a maximum of 1000 ml",[19],"Behavioral: Fluid restriction",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","Moltein PURE Protein Powder",[9],null,{"type":27,"name":15,"description":17,"armGroupLabels":28,"otherNames":25},"BEHAVIORAL",[15],[30],{"name":31,"affiliation":32,"role":33},"Mirjam Christ-Crain, Prof. MD","Universitätsspital Basel","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","+41 61 328 70 80","mirjam.christ-crain@usb.ch",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Cemile Bathelt","+41 61 556 54 07","cemile.bathelt@usb.ch",[44],{"facility":45,"status":46,"city":47,"state":25,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"University Hospital Basel","RECRUITING","Basel","4031","Switzerland","CH",{"type":52,"coordinates":53},"Point",[54,55],7.57327,47.55839,{"lat":55,"lon":54},[58],{"name":59,"role":36,"phone":37,"phoneExt":25,"email":38},"Mirjam Christ-Crain",{"type":61,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100579246","protein-supplementation-in-hyponatremia-due-to-the-syndrome-of-inappropriate-antidiuresis-100579246",false,"NCT06821802","Protein Supplementation in Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis","Effect of Protein Supplementation in Hospitalized Patients With Hyponatremia Due to the Syndrome of Inappropriate Antidiuresis - a Monocentric Randomized Open-label Pragmatic Active-controlled Trial - the TREASUREx Trial","TREASUREx","Inclusion Criteria:\n\n* Adult patients with confirmed SIAD during the hospital stay or at screening, defined by:\n* Plasma sodium concentration \\\u003C135 mmol\u002FL\n* Plasma osmolality \\\u003C300 mOsm\u002Fkg\n* Urine osmolality \\>100 mOsm\u002Fkg\n* Urine sodium concentration \\>30 mmol\u002FL\n* Clinical euvolemia (no signs of hypovolemia or hypervolemia)\n\nExclusion Criteria:\n\n* Lactose intolerance, milk protein allergy, soy allergy, nuts allergy, or hypersensitivity to components of the protein supplement.\n* Inborn metabolic disorders affecting carbohydrate, lipid, or protein metabolism.\n* Severe symptomatic hyponatremia requiring 3% NaCl or intensive care.\n* New (within the last five days) treatment with SGLT2 inhibitors, vaptans or oral urea\n* Uncontrolled severe hypothyroidism (untreated)\n* Uncontrolled adrenal insufficiency (morning cortisol \\\u003C150nmol\u002Fl)\n* eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m² (KDIGO G3b-5) or end-stage renal disease (dialysis)\n* Severe hepatic impairment or advanced symptomatic liver disease defined as past or current hepatic encephalopathy, liver cirrhosis Child C, or decompensated (bleeding, jaundice, hepatorenal syndrome)\n* Pregnancy, breastfeeding, or plans to become pregnant during the study.\n* End-of-life care\n* Lack of capacity or other reasons preventing from giving informed consent or following study procedures (e.g., due to language problems, psychological disorders, dementia, etc.)\n* Treatment with thiazid diuretic (must be stopped at least 48 hours before inclusion)\n\nPost-randomization Exclusion Criteria:\n\n* Type 1 diabetes or uncontrolled type 2 diabetes (HbA1c \\>8.0%)","ALL","18 Years",{"count":73,"type":74},70,"ESTIMATED","INTERVENTIONAL",[77],"NA","The goal of this study is to assess the impact of protein supplementation on hyponatremia caused by the syndrome of inappropriate antidiuresis during hospitalization.",[80,81],"Hyponatremia","Syndrome of Inappropriate Antidiuresis",[83,84,85,86],"dysregulated arginine vasopressin (AVP) secretion","increased renal AVP sensitivity","protein supplementation","fluid restriction","2025-07-07",{"date":89,"type":90},"2025-07-10","ACTUAL",{"date":92,"type":90},"2025-04-14",{"date":94,"type":74},"2027-04",{"name":5,"class":6},1]